Trial Profile
A Phase 2b/3, Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center Study to Investigate the Efficacy and Safety of Repeated Intravitreal Administration of KSI-301 in Subjects With Neovascular (Wet) Age-related Macular Degeneration
Status:
Discontinued
Phase of Trial:
Phase II/III
Latest Information Update: 12 Sep 2023
Price :
$35
*
At a glance
- Drugs Tarcocimab tedromer (Primary) ; Aflibercept
- Indications Wet age-related macular degeneration
- Focus Registrational; Therapeutic Use
- Acronyms DAZZE wet AMD; DAZZLE
- Sponsors Kodiak Sciences
- 02 Jun 2022 Status changed from active, no longer recruiting to discontinued as primary endpoint not met.
- 18 May 2022 This trial has been discontinued in Poland according to European Clinical Trials Database record.
- 29 Apr 2022 According to a Kodiak Sciences media release, data from this trial will be presented at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting and Retina World Congress 2022.